Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lüftner

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Anticancer Research|June 25, 2003
Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancerD Lüftner, A Richter, R Geppert, et al.
British Journal of Cancer|January 5, 2012
Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancerC F Jehn, L Böning, H Kröning, et al.
Anticancer Research|February 6, 2009
First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)C F Jehn, T Boulikas, A Kourvetaris, et al.
Journal of Cancer Research and Clinical Oncology|November 26, 1998
Gemcitabine for palliative treatment in metastatic breast cancerD Lüftner, B Flath, C Akrivakis, et al.
Anticancer Research|July 26, 2007
The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancerD Pollmann, S Siepmann, R Geppert, et al.
Cancer Chemotherapy and Pharmacology|September 20, 2001
A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancerI Olver, M Davy, D Lüftner, et al.
Journal of Neuroimmunology|October 7, 2015
Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depressionC F Jehn, B Becker, B Flath, et al.
Breast Cancer Research and Treatment|November 6, 2012
Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancerC F Jehn, B Flath, A Strux, et al.
Breast Cancer Research and Treatment|September 25, 2003
Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patientsD Lüftner, A Jung, P Schmid, et al.
Investigational New Drugs|December 16, 1998
Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I studyD Lüftner, B Flath, C Akrivakis, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Anticancer Research|June 25, 2003
Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancerD Lüftner, A Richter, R Geppert, et al.
British Journal of Cancer|January 5, 2012
Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancerC F Jehn, L Böning, H Kröning, et al.
Anticancer Research|February 6, 2009
First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)C F Jehn, T Boulikas, A Kourvetaris, et al.
Journal of Cancer Research and Clinical Oncology|November 26, 1998
Gemcitabine for palliative treatment in metastatic breast cancerD Lüftner, B Flath, C Akrivakis, et al.
Anticancer Research|July 26, 2007
The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancerD Pollmann, S Siepmann, R Geppert, et al.
Cancer Chemotherapy and Pharmacology|September 20, 2001
A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancerI Olver, M Davy, D Lüftner, et al.
Journal of Neuroimmunology|October 7, 2015
Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depressionC F Jehn, B Becker, B Flath, et al.
Breast Cancer Research and Treatment|November 6, 2012
Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancerC F Jehn, B Flath, A Strux, et al.
Breast Cancer Research and Treatment|September 25, 2003
Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patientsD Lüftner, A Jung, P Schmid, et al.
Investigational New Drugs|December 16, 1998
Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I studyD Lüftner, B Flath, C Akrivakis, et al.
Pageof 5